CoChat

Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Key Points: Hematopoietic cell–targeted antibody-drug conjugate preconditioning is highly effective for platelet gene therapy in hemophilia A mice. Platelet-specific FVIII gene therapy can effectively prevent a needle-induced knee joint injury in hemophilia A mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000516

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The influence of ADC-mediated conditioning on peripheral blood recovery and leukocyte chimerism in HA mice after 2bF8 lentiviral gene delivery to HSCs. CD45.2/FVIII null mice were preconditioned with CD45.2 and CD117 antibodies conjugated with SAP and transplanted with Sca-1 1 cells that were isolated from CD45.1/FVIII null donors and transduced with 2bF8LV. Additional untransduced Sca-1 -depleted cells were transplanted into some recipients. TBI (6.6-Gy) preconditioning was used as a control regimen in parallel. After $ 3 weeks of BM reconstitution, blood samples were collected for whole-blood count and flow cytometry analysis of leukocyte chimerism. (A) Schematic diagram of experimental design for 2bF8 gene therapy using (CD45.2 1 CD117)-ADC preconditioning. Sca-1 1 cells isolated from CD45.1/FVIII null donors were transduced with 2bF8LV and transplanted into CD45.2/FVIII null recipients preconditioned with (CD45.2 1 CD117)-ADC. Some recipients were cotransplanted with untransduced Sca-1 -depleted hematopoietic cells. (B) Leukocyte counts. (C) Platelet counts. (D) Hemoglobin levels. (E) Donor-derived leukocyte chimerism. (F) Percentage of animals with . 15% donor-derived leukocytes at 20 weeks after transplantation. (G) Percentage of donor-derived leukocytes at 20 weeks after transplantation. These results show that (CD45.2 1 CD117)-ADC conditioning does not result in prolonged cytopenias in HA mice and enables engraftment of 2bF8LV-transduced HSCs after plateletdirected gene therapy. * P , .05, ** P , .01, *** P , .001, **** P , .0001, ADC vs TBI, 2-way analysis of variance. Bio, biotin; SA, streptavidin.
Figure 1 The influence of ADC-mediated conditioning on peripheral blood recovery and leukocyte chimerism in HA mice after 2bF8 lentiviral gene delivery to HSCs. CD45.2/FVIII null mice were preconditioned with CD45.2 and CD117 antibodies conjugated with SAP and transplanted with Sca-1 1 cells that were isolated from CD45.1/FVIII null donors and transduced with 2bF8LV. Additional untransduced Sca-1 -depleted cells were transplanted into some recipients. TBI (6.6-Gy) preconditioning was used as a control regimen in parallel. After $ 3 weeks of BM reconstitution, blood samples were collected for whole-blood count and flow cytometry analysis of leukocyte chimerism. (A) Schematic diagram of experimental design for 2bF8 gene therapy using (CD45.2 1 CD117)-ADC preconditioning. Sca-1 1 cells isolated from CD45.1/FVIII null donors were transduced with 2bF8LV and transplanted into CD45.2/FVIII null recipients preconditioned with (CD45.2 1 CD117)-ADC. Some recipients were cotransplanted with untransduced Sca-1 -depleted hematopoietic cells. (B) Leukocyte counts. (C) Platelet counts. (D) Hemoglobin levels. (E) Donor-derived leukocyte chimerism. (F) Percentage of animals with . 15% donor-derived leukocytes at 20 weeks after transplantation. (G) Percentage of donor-derived leukocytes at 20 weeks after transplantation. These results show that (CD45.2 1 CD117)-ADC conditioning does not result in prolonged cytopenias in HA mice and enables engraftment of 2bF8LV-transduced HSCs after plateletdirected gene therapy. * P , .05, ** P , .01, *** P , .001, **** P , .0001, ADC vs TBI, 2-way analysis of variance. Bio, biotin; SA, streptavidin.CC-BY-NC-ND · From the PDF
Figure 2 Platelet FVIII expression in HA mice after 2bF8 lentiviral gene delivery to HSCs under ADC-mediated preconditioning. Blood samples were collected at various time points from 2bF8LV-transduced recipients under (CD45.2 1 CD117)-ADC -mediated preconditioning or TBI. Leukocytes and platelets were isolated. DNA was purified from leukocytes for PCR and qPCR analysis of proviral DNA. Platelet FVIII expression levels were determined by a chromogenic functional activity assay on platelet lysates. (A) PCR detection of the 2bF8 transgene expression cassette. 2bF8 proviral DNA was detected in leukocytes in all 2bF8LV-transduced recipients. Representative results are shown. FVIII null and WT mice were used as controls. (B) The average copy number of 2bF8 proviral DNA per cell in leukocytes from 2bF8LV-transduced recipients, as determined by qPCR. Heterozygous 2bF8-transgenic mice (2bF8 Tg 1 / 2 ) that were generated by our group via embryonic stem cell (ES) -mediated transgenesis with a known copy number (11 copies per cell) were used as a positive control. (C) The platelet FVIII expression levels in platelets from 2bF8LV-transduced recipients. Two of 6 recipients under (CD45.2 1 CD117)-ADC conditioning that received 2bF8LV-transduced Sca-1 cells failed to achieve platelet FVIII expression. All other recipients had sustained platelet FVIII expression. (D) Percentage of recipients with sustained platelet FVIII expression. (E) Platelet FVIII expression levels at 21 weeks after transplantation. These results demonstrate that sustained platelet FVIII expression can be achieved in HA mice after 2bF8 gene therapy with ADC-mediated preconditioning. * P , .05, *** P , .001, **** P , .0001, ADC vs TBI, 2-way analysis of variance.
Figure 2 Platelet FVIII expression in HA mice after 2bF8 lentiviral gene delivery to HSCs under ADC-mediated preconditioning. Blood samples were collected at various time points from 2bF8LV-transduced recipients under (CD45.2 1 CD117)-ADC -mediated preconditioning or TBI. Leukocytes and platelets were isolated. DNA was purified from leukocytes for PCR and qPCR analysis of proviral DNA. Platelet FVIII expression levels were determined by a chromogenic functional activity assay on platelet lysates. (A) PCR detection of the 2bF8 transgene expression cassette. 2bF8 proviral DNA was detected in leukocytes in all 2bF8LV-transduced recipients. Representative results are shown. FVIII null and WT mice were used as controls. (B) The average copy number of 2bF8 proviral DNA per cell in leukocytes from 2bF8LV-transduced recipients, as determined by qPCR. Heterozygous 2bF8-transgenic mice (2bF8 Tg 1 / 2 ) that were generated by our group via embryonic stem cell (ES) -mediated transgenesis with a known copy number (11 copies per cell) were used as a positive control. (C) The platelet FVIII expression levels in platelets from 2bF8LV-transduced recipients. Two of 6 recipients under (CD45.2 1 CD117)-ADC conditioning that received 2bF8LV-transduced Sca-1 cells failed to achieve platelet FVIII expression. All other recipients had sustained platelet FVIII expression. (D) Percentage of recipients with sustained platelet FVIII expression. (E) Platelet FVIII expression levels at 21 weeks after transplantation. These results demonstrate that sustained platelet FVIII expression can be achieved in HA mice after 2bF8 gene therapy with ADC-mediated preconditioning. * P , .05, *** P , .001, **** P , .0001, ADC vs TBI, 2-way analysis of variance.CC-BY-NC-ND · From the PDF
Figure 3 The influence of ADC-mediated preconditioning on blood cell lineage reconstitution after HSCT. Sca-1 cells were isolated from CD45.2/CAG-GFP -transgenic (CD45.2/GFP Tg ) mice and transplanted into CD45.2/FVIII null mice under (CD45.2 1 CD117)-ADC preconditioning. Platelets were stained with CD41 antibody. Leukocytes were stained with CD45.2, CD4, CD8, and B220 antibodies, and donor-derived GFP 1 chimerism was analyzed by flow cytometry at various time points after HSCT. (A) Schematic diagram of experimental design for GFP Tg HSCT using (CD45.2 1 CD117)-ADC preconditioning. (B) Platelet chimerism. (C) Leukocyte chimerism. (D) CD4 T cell chimerism. (E) CD8 T cell chimerism. (F) B-cell chimerism. (G) Myeloid chimerism. (H) Sustained high levels of platelet chimerism in primary and secondary transplant recipients. (I) Sustained leukocyte chimerism in primary and secondary transplant recipients. These results demonstrate that (CD45.2 1 CD117)-ADC preconditioning is favorable for platelet lineage reconstitution after HSCT.
Figure 3 The influence of ADC-mediated preconditioning on blood cell lineage reconstitution after HSCT. Sca-1 cells were isolated from CD45.2/CAG-GFP -transgenic (CD45.2/GFP Tg ) mice and transplanted into CD45.2/FVIII null mice under (CD45.2 1 CD117)-ADC preconditioning. Platelets were stained with CD41 antibody. Leukocytes were stained with CD45.2, CD4, CD8, and B220 antibodies, and donor-derived GFP 1 chimerism was analyzed by flow cytometry at various time points after HSCT. (A) Schematic diagram of experimental design for GFP Tg HSCT using (CD45.2 1 CD117)-ADC preconditioning. (B) Platelet chimerism. (C) Leukocyte chimerism. (D) CD4 T cell chimerism. (E) CD8 T cell chimerism. (F) B-cell chimerism. (G) Myeloid chimerism. (H) Sustained high levels of platelet chimerism in primary and secondary transplant recipients. (I) Sustained leukocyte chimerism in primary and secondary transplant recipients. These results demonstrate that (CD45.2 1 CD117)-ADC preconditioning is favorable for platelet lineage reconstitution after HSCT.CC-BY-NC-ND · From the PDF
Figure 4 The impact of the addition of CD4-ADC or CD8-ADC on the efficacy of (CD45.2 1 CD117)-ADC preconditioning in platelet-specific FVIII gene therapy of HA mice. CD45.2/FVIII null mice were preconditioned with (CD45.2 1 CD117)-ADC plus CD8-ADC or CD4-ADC and received 2bF8LV-transduced CD45.1/FVIII null Sca-1 1 cells. TBI was used as a control preconditioning regimen in parallel. After $ 3 weeks of BM reconstitution, blood samples were collected from recipients post-HSCT at various time points for chimerism analysis, qPCR analysis, and platelet lysate FVIII activity assay. (A) Schematic diagram of experimental design for 2bF8 gene therapy using (CD45.2 1 CD117)-ADC plus CD4-ADC or CD8-ADC preconditioning. (B) Leukocyte chimerism analyzed by flow cytometry. (C) Percentage of donor-derived leukocytes at 20 weeks after HSCT. (D) Platelet FVIII expression levels determined by platelet lysate FVIII activity assay. (E) Platelet FVIII expression levels at 21 weeks after HSCT. (F) Average copy number of 2bF8 proviral DNA per cell from peripheral blood leukocytes, as determined by qPCR. Homozygous 2bF8-transgenic mice (LV17/18 Tg 1 / 1 ) that were generated by our group via 2bF8LV-mediated transgenesis with a known copy number (4 copies per cell) were used as a positive control. (G) Platelet FVIII expression in sequential BMT recipients under ADC-mediated preconditioning. Sixty weeks after HSCT, BM cells were collected from some primary (1°) recipients and transplanted into secondary (2°) recipients under the same conditioning regimen that donors received: (CD45.2 1 CD117 1 CD4)-ADC or (CD45.2 1 CD117 1 CD8)-ADC. Animals were analyzed monthly. The levels of platelet FVIII expression from the 1° recipients were averaged from the last 3 time points. The 2° recipients ' platelet FVIII levels were averaged from the 3 time points after sequential transplantation. These results demonstrate that the addition of CD4-ADC or CD8-ADC can enhance the efficacy of (CD45.2 1 CD117)-ADC preconditioning in platelet-specific FVIII gene therapy in HA mice.
Figure 4 The impact of the addition of CD4-ADC or CD8-ADC on the efficacy of (CD45.2 1 CD117)-ADC preconditioning in platelet-specific FVIII gene therapy of HA mice. CD45.2/FVIII null mice were preconditioned with (CD45.2 1 CD117)-ADC plus CD8-ADC or CD4-ADC and received 2bF8LV-transduced CD45.1/FVIII null Sca-1 1 cells. TBI was used as a control preconditioning regimen in parallel. After $ 3 weeks of BM reconstitution, blood samples were collected from recipients post-HSCT at various time points for chimerism analysis, qPCR analysis, and platelet lysate FVIII activity assay. (A) Schematic diagram of experimental design for 2bF8 gene therapy using (CD45.2 1 CD117)-ADC plus CD4-ADC or CD8-ADC preconditioning. (B) Leukocyte chimerism analyzed by flow cytometry. (C) Percentage of donor-derived leukocytes at 20 weeks after HSCT. (D) Platelet FVIII expression levels determined by platelet lysate FVIII activity assay. (E) Platelet FVIII expression levels at 21 weeks after HSCT. (F) Average copy number of 2bF8 proviral DNA per cell from peripheral blood leukocytes, as determined by qPCR. Homozygous 2bF8-transgenic mice (LV17/18 Tg 1 / 1 ) that were generated by our group via 2bF8LV-mediated transgenesis with a known copy number (4 copies per cell) were used as a positive control. (G) Platelet FVIII expression in sequential BMT recipients under ADC-mediated preconditioning. Sixty weeks after HSCT, BM cells were collected from some primary (1°) recipients and transplanted into secondary (2°) recipients under the same conditioning regimen that donors received: (CD45.2 1 CD117 1 CD4)-ADC or (CD45.2 1 CD117 1 CD8)-ADC. Animals were analyzed monthly. The levels of platelet FVIII expression from the 1° recipients were averaged from the last 3 time points. The 2° recipients ' platelet FVIII levels were averaged from the 3 time points after sequential transplantation. These results demonstrate that the addition of CD4-ADC or CD8-ADC can enhance the efficacy of (CD45.2 1 CD117)-ADC preconditioning in platelet-specific FVIII gene therapy in HA mice.CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
Figure 6 Immune responses in HA mice after platelet-specific gene therapy with hematopoietic cell -targeted ADC preconditioning. For Treg analysis, blood samples were collected from 2bF8LV-transduced recipients, and CD4 1 Foxp3 1 Tregs were analyzed by flow cytometry. For immune response studies, $ 24 weeks after HSCT, recipients were immunized with rhF8 by IV infusion weekly for 4 weeks. One week after the last immunization, plasmas were collected, and inhibitor titers were determined by Bethesda assay. (A) Percentage of total Tregs in 2bF8LV-transduced recipients at 11 weeks after gene therapy. The statistical differences between the groups of transduced recipients and CD45.1/FVIII null controls were analyzed using 1-way analysis of variance (ANOVA), followed by Dunnett ' s multiple-comparisons test. (B) Percentage of donorderived Tregs in 2bF8LV-transduced recipients at 11 weeks after gene therapy. The statistical differences between the groups of transduced recipients and CD45.1/FVIII null controls were analyzed using 1-way ANOVA, followed by Dunnett ' s multiple-comparisons test. (C) The anti-FVIII inhibitor titers in 2bF8LV-transduced recipients after challenge with rhF8 at a dose of 100 U/kg per week for 4 weeks. Data from the 2 2bF8LV-transduced recipients in the (CD45.2 1 CD117)-ADC group that did not have sustained platelet FVIII expression are presented as a separate group. The statistical differences between the groups were analyzed using 2-way ANOVA, followed by Tukey ' s multiplecomparisons test. (D) The anti-FVIII inhibitor titers in 2bF8LV-transduced recipients after challenge with rhF8 at a dose of 200 U/kg per week for 4 weeks. The statistical differences between the groups were analyzed using the Mann-Whitney U test. (E) The incidence of inhibitor development in 2bF8LV-transduced recipients after challenge with rhF8 at a dose of 200 U/kg per week for 4 weeks. The statistical difference between the groups was analyzed using Fisher ' s exact test. These data demonstrate that 2bF8 lentiviral gene delivery to HSCs under ADC-mediated preconditioning can suppress anti-FVIII immune responses. * P , .05, ** P , .01, *** P , .001, **** P , .0001.
Figure 6 Immune responses in HA mice after platelet-specific gene therapy with hematopoietic cell -targeted ADC preconditioning. For Treg analysis, blood samples were collected from 2bF8LV-transduced recipients, and CD4 1 Foxp3 1 Tregs were analyzed by flow cytometry. For immune response studies, $ 24 weeks after HSCT, recipients were immunized with rhF8 by IV infusion weekly for 4 weeks. One week after the last immunization, plasmas were collected, and inhibitor titers were determined by Bethesda assay. (A) Percentage of total Tregs in 2bF8LV-transduced recipients at 11 weeks after gene therapy. The statistical differences between the groups of transduced recipients and CD45.1/FVIII null controls were analyzed using 1-way analysis of variance (ANOVA), followed by Dunnett ' s multiple-comparisons test. (B) Percentage of donorderived Tregs in 2bF8LV-transduced recipients at 11 weeks after gene therapy. The statistical differences between the groups of transduced recipients and CD45.1/FVIII null controls were analyzed using 1-way ANOVA, followed by Dunnett ' s multiple-comparisons test. (C) The anti-FVIII inhibitor titers in 2bF8LV-transduced recipients after challenge with rhF8 at a dose of 100 U/kg per week for 4 weeks. Data from the 2 2bF8LV-transduced recipients in the (CD45.2 1 CD117)-ADC group that did not have sustained platelet FVIII expression are presented as a separate group. The statistical differences between the groups were analyzed using 2-way ANOVA, followed by Tukey ' s multiplecomparisons test. (D) The anti-FVIII inhibitor titers in 2bF8LV-transduced recipients after challenge with rhF8 at a dose of 200 U/kg per week for 4 weeks. The statistical differences between the groups were analyzed using the Mann-Whitney U test. (E) The incidence of inhibitor development in 2bF8LV-transduced recipients after challenge with rhF8 at a dose of 200 U/kg per week for 4 weeks. The statistical difference between the groups was analyzed using Fisher ' s exact test. These data demonstrate that 2bF8 lentiviral gene delivery to HSCs under ADC-mediated preconditioning can suppress anti-FVIII immune responses. * P , .05, ** P , .01, *** P , .001, **** P , .0001.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 51

Metadata

Authors
Gao, C., Schroeder, J. A., Xue, F., Jing, W., Cai, Y., Scheck, A., Subramaniam, S., Rao, S., Weiler, H., Czechowicz, A., & Shi, Q.
Affiliations
  • Harbin Medical University (CN)
  • Children's Hospital of Wisconsin (US)
  • Versiti Blood Center of Wisconsin (US)
  • Boston Children's Hospital (US)
  • Blood Research Institute, Versiti Wisconsin, Milwaukee, WI;
Venue
Blood Advances
Published
2019-09-12
Volume
3
Issue
18
Pages
2700-2711
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2972398700
Cited by
51
References
45
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 7 · 2022: 8 · 2021: 13 · 2020: 9
FWCI
5.30
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • University of Pennsylvania
  • Midwest Athletes Against Childhood Cancer
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (HL-102035, R01HL102035)
  • National Cancer Institute (R01CA204231)
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
hemophilia A, factor VIII, hematopoietic stem cell gene therapy, saporin, CD117, CD8, immune tolerance, lentiviral vectors, engraftment, hemostasis, hemarthrosis
MeSH terms
Animals, Blood Platelets, Hemophilia A, Humans, Male, Genetic Therapy, Immunoconjugates, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000516
The paper
Gao, C., Schroeder, J. A., Xue, F., Jing, W., Cai, Y., Scheck, A., Subramaniam, S., Rao, S., Weiler, H., Czechowicz, A., & Shi, Q. (2019). Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.